Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Protein Kinases and Phosphatases

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...

Protein Kinases and Phosphatases

Protein Kinases and Phosphatases

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Eukaryotic Transcription Inhibitors

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...

Predicting Molecular Geometry

Predicting Molecular Geometry

VSEPR Theory for Determination of Electron Pair Geometries

The Extracellular Matrix

The Extracellular Matrix

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

GluD1 is localized at cholinergic synapses and is an acetylcholine receptor.

Molecular psychiatry·2026

Same author

DksA inhibitors against intracellular and persistent <i>Salmonella</i> are effective in acute models of infection.

Science advances·2026

Same author

A Computational Community Blind Challenge on Pan-Coronavirus Drug Discovery Data.

Journal of chemical information and modeling·2026

Same author

Thioredoxin interacting protein (TXNIP), a redox regulator, mediates the RAPGEF3/4 signaling dependency in primary melanoma.

bioRxiv : the preprint server for biology·2026

Same author

Protein Set Transformer: a protein-based genome language model to power high-diversity viromics.

Nature communications·2025

Same author

MPAC: a computational framework for inferring pathway activities from multi-omic data.

Bioinformatics (Oxford, England)·2025

Search research articles

Related Experiment Video

Updated: Jan 21, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Predicting kinase inhibitors using bioactivity matrix derived informer sets.

Huikun Zhang¹, Spencer S Ericksen², Ching-Pei Lee³

¹Department of Statistics, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.

Plos Computational Biology

|August 6, 2019

Summary

This summary is machine-generated.

Selecting an informer set using chemogenomic data improves drug discovery. The Informer-Based-Ranking (IBR) approach enhances virtual screening by prioritizing compounds with higher probabilities of activity against new targets.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Protein Kinase C-delta Inhibitor Peptide Formulation using Gold Nanoparticles

Protein Kinase C-delta Inhibitor Peptide Formulation using Gold Nanoparticles

Published on: March 9, 2019

Related Experiment Videos

Last Updated: Jan 21, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Protein Kinase C-delta Inhibitor Peptide Formulation using Gold Nanoparticles

Protein Kinase C-delta Inhibitor Peptide Formulation using Gold Nanoparticles

Published on: March 9, 2019

Area of Science:

Medicinal Chemistry
Computational Drug Discovery
Cheminformatics

Background:

Drug discovery relies on predicting compound activity against biological targets.
Virtual screening aims to identify active compounds but often lacks sufficient data for supervised learning.
Traditional library selection methods (diversity-based, random) may not yield enough active compounds.

Purpose of the Study:

To compare different methods of using chemogenomic data to select small informer sets for screening.
To develop and validate an Informer-Based-Ranking (IBR) approach for compound selection.
To demonstrate the utility of IBR in prospective drug discovery screening.

Main Methods:

Utilized chemogenomic data from the Published Kinase Inhibitor Sets (PKIS).
Developed the Informer-Based-Ranking (IBR) method to select informer sets based on bioactivity data.
Tested informer compounds on novel kinase targets and predicted activity of remaining compounds.

Main Results:

IBR effectively selected informative compound sets.
Predicted activities correlated well with experimental screening results.
IBR strategies proved useful in prospective screening against new kinase targets.

Conclusions:

Cheminogenomic data can significantly enhance the selection of screening libraries.
The Informer-Based-Ranking (IBR) approach offers a data-driven strategy for prioritizing compounds in early drug discovery.
IBR facilitates more efficient identification of active compounds, especially when data is scarce.